

1 PRESCRIBING BLOOD COMPONENTS

Date Issued: January 2005
Date Revised: April 2011
Review Date: April 2013
Authorised by: KEMH Transfusion Committee
Review Team: KEMH Transfusion Committee

1.4 Clinical Indications for Blood Products
Section 1
Transfusion Medicine Protocols
Women's & Newborn Health Services
Perth Western Australia

1.4 CLINICAL INDICATIONS FOR BLOOD PRODUCTS

Reference is made to [The National Health and Medical Research Council \(NHMRC\) clinical practice guidelines on Blood and Blood Products:](#)

To assist clinicians to have readily available information the Working Party that developed the Guidelines, also developed a series of documents and summary cards tailored to meet the needs of the clinicians. In addition, the Working Party recognised the importance of consumer issues and processes for informed consent.

[Appropriate Use of Red Blood Cells](#)

[Appropriate Use of Platelets](#)

[Appropriate Use of Fresh Frozen Plasma and Cryoprecipitate](#)

The **Clinical Practice Guidelines for the use of Blood Components** aim to:

- Improve the consistency and appropriateness of transfusion practice;
- Promote the integration of quality management systems into transfusion practice;
- Reduce the overall number of transfusion-related complications;
- Increase consumer awareness of the benefits and risks of blood component therapy;
- Conserve a limited resource.